Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Change in Accured Expenses (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Change in Accured Expenses for 7 consecutive years, with $2.6 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Accured Expenses rose 202.54% year-over-year to $2.6 million; the TTM value through Mar 2026 reached $1.3 million, up 205.79%, while the annual FY2025 figure was -$3.8 million, 931.8% down from the prior year.
  • Change in Accured Expenses hit $2.6 million in Q1 2026 for Barinthus Biotherapeutics, up from -$453000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.6 million in Q3 2022 and bottomed at -$4.3 million in Q4 2022.
  • Average Change in Accured Expenses over 5 years is $117235.3, with a median of -$453000.0 recorded in 2025.
  • On a YoY basis, Change in Accured Expenses climbed as much as 2720.37% in 2022 and fell as far as 479.63% in 2022.
  • Barinthus Biotherapeutics' Change in Accured Expenses stood at -$4.3 million in 2022, then grew by 24.89% to -$3.2 million in 2023, then skyrocketed by 161.22% to $2.0 million in 2024, then plummeted by 122.83% to -$453000.0 in 2025, then skyrocketed by 670.86% to $2.6 million in 2026.
  • According to Business Quant data, Change in Accured Expenses over the past three periods came in at $2.6 million, -$453000.0, and -$573000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.